SARS CoV 2 News and Research

RSS

Non-pharmaceutical interventions effectively reduce COVID case burden in the United States

A new study analyzes the impact of non-pharmaceutical interventions in the United States against SARS-CoV-2 transmission.

3 Oct 2021

Persistent leukocyte changes three months after mild SARS-CoV-2 infection

A recent study discusses the rate of changes in peripheral blood white cells in individuals who have recovered from SARS-CoV-2 infection.

3 Oct 2021

Important factors that determine the child clinical COVID-19 attack ratio

A new modeling study aimed to determine the attack ratio among children between the ages of 0-11 years in Ontario, Canada.

3 Oct 2021

COVID-19 may trigger hyperglycemia by disrupting key metabolic signals to cause severe disease

COVID-19 may bring high risks of severe disease and death in many patients by disrupting key metabolic signals and thereby triggering hyperglycemia, according to a new study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.

2 Oct 2021

Cancer patients on chemotherapy have lower immune response to COVID-19 vaccine, study finds

The COVID-19 pandemic has been an especially stressful time for cancer patients undergoing chemotherapy, which attacks not only the cancer, but also the immune cells needed to defend the body from infections.

2 Oct 2021

CDC awards $15.88 million to Wayne State University to study viral infection surveillance

The U.S. Centers for Disease Control and Prevention has awarded $15.88 million to the Wayne State University School of Medicine's Department of Emergency Medicine to be the epicenter of a national study on viral infections that present in emergency departments across the county.

1 Oct 2021

Two-mAb cocktail prevents SARS-CoV-2 infection, study suggests

A promising study shows that a combination of two monoclonal antibodies effectively neutralized SARS-CoV-2 in monkeys and proved efficacious against newer variants of concern in vitro.

1 Oct 2021

Enveloped virus-like particle based vaccines potentially broaden immunity against SARS-CoV-2 variants

A new preprint describes promising results with a novel vaccine candidate designed to improve the breadth of neutralization.

1 Oct 2021

Structure of monoclonal antibody that can potently neutralize SARS-CoV-2 and variants of concern

A new preprint deals with the analysis of the monoclonal antibody J08, which was capable of powerful neutralization of the wildtype SARS-CoV-2, and its VOCs.

1 Oct 2021

Persistence of humoral immune response in SARS-CoV-2 convalescent individuals a year after infection

A new study reported the persistence of immune responses over twelve months after natural infection.

1 Oct 2021

Similar viral load in vaccinated and unvaccinated individuals infected with SARS-CoV-2 Delta variant

Researchers evaluated Ct-values among distinct groups, namely, a) completely vaccinated and unvaccinated individuals and b) asymptomatic and symptomatic individuals at the time of testing.

1 Oct 2021

The extent to which COVID-19 vaccination reduces transmission varies with vaccine type and SARS-CoV-2 strain

Researchers from the University of Oxford have been examining the impact of vaccination on the spread of the Alpha and Delta variants through the population.

1 Oct 2021

Study finds US pediatric COVID-19 cases are higher than expected

Researchers from the CDC have investigated differences in seroprevalence across pediatric age groups to estimate an infection to case ratio.

1 Oct 2021

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Real-world data looking at biologic treatment and vaccine hesitancy in psoriasis patients is being presented today at EADV’s 30th Congress.

1 Oct 2021

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Is one COVID vaccine better than the other? Four current vaccines — Moderna, Pfizer-BioNTech, Johnson & Johnson, and AstraZeneca — are highly effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but a new medRxiv* study suggests the level of protection varies.

30 Sep 2021

New approach reveals ‘protein partners’ that may contribute to unusual pathologies of COVID-19

COVID-19 not only causes symptoms characteristic of a typical respiratory disorder, but has also been known to trigger a wide range of other symptoms in people who had been infected, some lasting even long after individuals test negative for the virus.

30 Sep 2021

Moderna vaccine reduced viral load and protected against SARS-CoV-2 variants in new phase 3 trial

Coronavirus research has shown that higher viral loads are associated with severe COVID-19 infection. But new results from the phase III Coronavirus Efficacy (COVE) clinical trial find the Moderna vaccine reduces severe acute respiratory coronavirus 2 (SARS-CoV-2) viral load and viral shedding.

30 Sep 2021

Non-severe COVID-19 may elicit more durable memory B cell response than severe COVID-19

A recent study conducted by researchers from the US aimed to measure the impact of severity of COVID-19 on memory B cell response and characterize changes in the memory B cell compartment during the period between recovery and five months after symptom onset. This study is available on the bioRxiv* preprint server.

30 Sep 2021

University of Oxford and Oracle's Global Pathogen Analysis System helping researchers to combat COVID-19

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle's Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent.

30 Sep 2021

Early-stage interaction of monocytes with SARS-CoV-2-infected epithelial cell decides COVID-19 severity

A team of scientists from the USA and France has recently unveiled the mechanism of immune dysregulation in coronavirus disease 2019 (COVID-19) patients by analyzing the early-stage interaction between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected epithelial cells and immune cells. The study is currently available on the bioRxiv* preprint server.

30 Sep 2021

SARS CoV 2 News and Research

Non-pharmaceutical interventions effectively reduce COVID case burden in the United States

Persistent leukocyte changes three months after mild SARS-CoV-2 infection

Important factors that determine the child clinical COVID-19 attack ratio

COVID-19 may trigger hyperglycemia by disrupting key metabolic signals to cause severe disease

Cancer patients on chemotherapy have lower immune response to COVID-19 vaccine, study finds

CDC awards $15.88 million to Wayne State University to study viral infection surveillance

Two-mAb cocktail prevents SARS-CoV-2 infection, study suggests

Enveloped virus-like particle based vaccines potentially broaden immunity against SARS-CoV-2 variants

Structure of monoclonal antibody that can potently neutralize SARS-CoV-2 and variants of concern

Persistence of humoral immune response in SARS-CoV-2 convalescent individuals a year after infection

Similar viral load in vaccinated and unvaccinated individuals infected with SARS-CoV-2 Delta variant

The extent to which COVID-19 vaccination reduces transmission varies with vaccine type and SARS-CoV-2 strain

Study finds US pediatric COVID-19 cases are higher than expected

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

New approach reveals ‘protein partners’ that may contribute to unusual pathologies of COVID-19

Moderna vaccine reduced viral load and protected against SARS-CoV-2 variants in new phase 3 trial

Non-severe COVID-19 may elicit more durable memory B cell response than severe COVID-19

University of Oxford and Oracle's Global Pathogen Analysis System helping researchers to combat COVID-19

Early-stage interaction of monocytes with SARS-CoV-2-infected epithelial cell decides COVID-19 severity

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News